With more than 30 oncology partners, Gilead lays out its 2030 vision of 20 new approvals
Gilead has had a rocky history in oncology.
A brief recount of the past few quarters: Trodelvy, the crown jewel of Gilead’s $21 billion Immunomedics deal, underwhelmed Wall Street last month after the company kept details on the drug’s treatment of HR+/HER2- breast cancer mostly under wraps. There’s also the partial holds, some of which were recently lifted, on the “breakthrough” magrolimab from the $4.9 billion Forty Seven purchase. The CD47 drug had already been through hurdles with delayed data readouts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.